Initial duloxetine prescription dose and treatment adherence and persistence in patients with major depressive disorder

International Clinical Psychopharmacology

Volumn 25, Issue 6, 2010, Pages 315-322

  Liu, Xianchen ^a,b   Gelwicks, Steve ^a   Faries, Douglas E ^a   Able, Stephen L ^a  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

adherence; duloxetine; major depressive disorder; managed care; persistence

Indexed keywords

DULOXETINE; METHYLPHENIDATE; MODAFINIL; VENLAFAXINE;

ADULT; ARTICLE; COMORBIDITY; DIABETES MELLITUS; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; HUMAN; LOW BACK PAIN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; OSTEOARTHRITIS; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DRUG PRESCRIPTIONS; FEMALE; HUMANS; MALE; MANAGED CARE PROGRAMS; MEDICAL RECORDS; MEDICATION ADHERENCE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; THIOPHENES; TIME FACTORS; YOUNG ADULT;

EID: 77958494094     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e32833db42e     Document Type: Article

References (42)

1. Balkrishnan R, Joish VN, Yang T, Jayawant SS, Mullins CD (2008). The economic burden associated with SSRI treatment failure in a managed care population. J Med Econ 11:601-610.
2. Bech P, Kajdasz DK, Porsdal V (2006). Dose-response relationship of duloxetine in placebo-controlled clinical trials in patients with major depressive disorder. Psychopharmacology (Berl) 188:273-280.
3. Birnbaum HG, Cremieux PY, Greenberg PE, LeLorier J, Ostrander JA, Venditti L (1999). Using healthcare claims data for outcomes research and pharma-coeconomic analyses. Pharmacoeconomics 16:1-8.
4. Bosworth HB, Voils CI, Potter GG, Steffens DC (2008). The effects of antidepressant medication adherence as well as psychosocial and clinical factors on depression outcome among older adults. Int J Geriatr Psychiatry 23:129-134.
5. Bulloch AG, Patten SB (2010). Non-adherence with psychotropic medications in the general population. Soc Psychiatry Psychiatr Epidemiol 45:47-56.
6. Caley CF, Kando JC (2002). SSRI efficacy-finding the right dose. J Psychiatr Pract 8:33-40.
7. Cantrell CR, Eaddy MT, Shah MB, Regan TS, Sokol MC (2006). Methods for evaluating patient adherence to antidepressant therapy: a real-world comparison of adherence and economic outcomes. Med Care 44:300-303.
8. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, et al. (2008). Medication compliance and persistence: terminology and definitions. Value Health 11:44-47.
9. Demyttenaere K, Enzlin P, Dewe W, Boulanger B, De Bie J, De Troyer W, et al. (2001). Compliance with antidepressants in a primary care setting, 2: the influence of gender and type of impairment. J Clin Psychiatry 62 (Suppl 22): 34-37.
10. Demyttenaere K, Adelin A, Patrick M,Walthere D, Katrien de B, Michele S (2008). Six-month compliance with antidepressant medication in the treatment of major depressive disorder. Int Clin Psychopharmacol 23:36-42.
11. Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA (2002a). Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 63:308-315.
12. Detke MJ, Lu Y, Goldstein DJ, McNamara RK, Demitrack MA (2002b). Duloxetine 60mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 36:383-390.
13. Eaddy MT, Druss BG, Sarnes MW, Regan TS, Frankum LE (2005). Relationship of total health care charges to selective serotonin reuptake inhibitor utilization patterns including the length of antidepressant therapy-results from a managed care administrative claims database. J Manag Care Pharm 11:145-150.
14. Garrison LP Jr, Neumann PJ, Erickson P, Marshall D, Mullins CD (2007). Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. Value Health 10:326-335.
15. Girardi P, Pompili M, Innamorati M, Mancini M, Serafini G, Mazzarini L, et al. (2009). Duloxetine in acute major depression: review of comparisons to placebo and standard antidepressants using dissimilar methods. Hum Psychopharmacol 24:177-190.
16. Iosifescu DV, Bankier B, Fava M (2004). Impact of medical comorbid disease on antidepressant treatment of major depressive disorder. Curr Psychiatry Rep 6:193-201. (Pubitemid 38906845)
17. Iosifescu DV, Clementi-Craven N, Fraguas R, Papakostas GI, Petersen T, Alpert JE, et al. (2005). Cardiovascular risk factors may moderate pharmacological treatment effects in major depressive disorder. Psychosom Med 67:703-706.
18. Kelin K, Berk M, Spann M, Sagman D, Raskin J, Walker D, et al. (2010). Duloxetine 60 mg/day for the prevention of depressive recurrences: post hoc analyses from a recurrence prevention study. Int J Clin Pract 64:719-726.
19. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE (2005b). Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:617-627. (Pubitemid 40973437)
20. Kroenke K, Krebs EE, Bair MJ (2009). Pharmacotherapy of chronic pain: a synthesis of recommendations from systematic reviews. Gen Hosp Psychiatry 31:206-219.
21. Lin EH, Von Korff M, Ludman EJ, Rutter C, Bush TM, Simon GE, et al. (2003)., Enhancing adherence to prevent depression relapse in primary care. Gen Hosp Psychiatry 25:303-310.
22. Liu X, Chen Y, Faries D, Blackham J, Watson P (2009a). Adherence and persistence to branded and generic antidepressants in the usual treatment of patients with major depressive disorder. Presented at 22nd Annual U.S. Psychiatric & Mental Health Congress; Las Vegas, Nevada.
23. Liu X, Chen Y, Faries D, Coleman A, Miner C, Swindle R (2009b). Impact of comorbidities on antidepressant initiation: duloxetine, venlafaxine XR, and escitalopram versus generic SSRIs. Presented at American Psychiatric Association-61st Institute on Psychiatric Services; New York.
24. Liu X, Gelwicks S, Watson P, Able S, Faries D, Watson P, et al. (2009c) Initial high-dose prescription of duloxetine in patients with MDD: demographic and clinical predictors. Presented at American College of Clinical Pharmacology, 38th Annual Meeting; San Antonio, Texas.
25. Liu X, Ye W, Wohlreich M, Martinez J, Kivior J (2009d). Chronic pain associated with increased use of hypnotics and anxiolytics in patients with major depressive disorder. Presented at 162nd Annual Meeting of the American Psychiatric Association; San Francisco, California.
26. Liu X, Tepper P, Watson P (2010). Adherence and persistence with duloxetine and hospitalization in patients with major depressive disorder. Presented at 22nd Annual Meeting of the Academy of Managed Care Pharmacy.
27. Marcus SC, Hassan M, Olfson M (2009). Antidepressant switching among adherent patients treated for depression. Psychiatr Serv 60:617-623.
28. Melfi CA, Chawla AJ, Croghan TW, Hanna MP, Kennedy S, Sredl K (1998). The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry 55:1128-1132.
29. Mullins CD, Shaya FT, Zito JM, Obeidat N, Naradzay J, Harrison DJ (2006). Effect of initial ziprasidone dose on treatment persistence in schizophrenia. Schizophr Res 83:277-284.
30. Nantz E, Liu-Seifert H, Skljarevski V (2009). Predictors of premature discontinuation of treatment in multiple disease states. Patient Prefer Adherence 3:31-43.
31. Ong JC, Gress JL, San Pedro-Salcedo MG, Manber R (2009). Frequency and predictors of obstructive sleep apnea among individuals with major depressive disorder and insomnia. J Psychosom Res 67:135-141.
32. Papakostas GI (2009). Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder. J Clin Psychiatry 70 (Suppl 6):16-25.
33. Pompili M, Serafini G, Del Casale A, Rigucci S, Innamorati M, Girardi P, et al. (2009). Improving adherence in mood disorders: the struggle against relapse, recurrence and suicide risk. Expert Rev Neurother 9:985-1004.
34. Pritchett YL, Marciniak MD, Corey-Lisle PK, Berzon RA, Desaiah D, Detke MJ (2007). Use of effect size to determine optimal dose of duloxetine in major depressive disorder. J Psychiatr Res 41:311-318.
35. Sood N, Treglia M, Obenchain RL, Dulisse B, Melfi CA, Croghan TW (2000). Determinants of antidepressant treatment outcome. Am J Manag Care 6:1327-1336.
36. Stafford RS, MacDonald EA, Finkelstein SN (2001). National patterns of medication treatment for depression, 1987-2001. Prim Care Companion J Clin Psychiatry 3:232-235.
37. Thompson D, Buesching D, Gregor KJ, Oster G (1996). Patterns of antidepressant use and their relation to costs of care. Am J Manag Care 2:1239-1246.
38. Trivedi MH, Fava M,Wisniewski SR, Thase ME, Quitkin F,Warden D, et al. (2006). Medication augmentation after the failure of SSRIs for depression. N Engl J Med 354:1243-1252.
39. Vaccarino AL, Sills TL, Evans KR, Kalali AH (2009). Multiple pain complaints in patients with major depressive disorder. Psychosom Med 71:159-162.
40. Warden D, Trivedi MH, Wisniewski SR, Davis L, Nierenberg AA, Gaynes BN, et al. (2007). Predictors of attrition during initial (citalopram) treatment for depression: a STAR*D report. Am J Psychiatry 164:1189-1197.
41. World Health Organization (2004). The World Health Report 2004: changing history, annex Table 3: burden of disease in DALYs by cause, sex, and mortality stratum in WHO regions, estimates for 2002. Geneva: World Health Organization.
42. Ye WY, Zhao Y, Robinson R, Swindle R (2008). Predictors of treatment initiation with duloxetine compared with venlafaxine XR among patients with major depressive disorder in US managed-care setting. Presented at 13th International Meeting of the International Society for Pharmacoeconomics and Outcomes Research; Toronto.